Literature DB >> 25520148

Schistosoma mansoni soluble egg antigens enhance T cell responses to a newly identified HIV-1 Gag H-2b epitope.

Cac T Bui1, Lisa M Shollenberger1, Yvonne Paterson2, Donald A Harn3.   

Abstract

Schistosome infection induces significant T helper type 2 (Th2) and anti-inflammatory immune responses and has been shown to negatively impact vaccine efficacy. Our goal was to determine if the administration of schistosome soluble egg antigens (SEA) would negatively influence the induction of cytotoxic T lymphocyte (CTL) and Th1-type T cell responses to an HIV candidate vaccine in the Th1-biased C57BL/6 mouse strain. Initial experiments failed, as we were unable to detect any response to the defined class I epitope for HIV-1 IIIB Gag. Therefore, we initiated an epitope mapping study to identify C57BL/6 (H-2(b)) T cell epitopes in HIV-1 IIIB Gag in order to perform the experiments. This analysis defined two previously unreported minimal class I H-2(b) and class II I-A(b) epitopes for HIV-1 IIIB Gag. The newly defined HIV-1 IIIB Gag epitopes were used to evaluate the influence of SEA on the generation of CTL and Th1-type HIV-1 IIIB Gag responses. Surprisingly, in contrast to our hypothesis, we observed that the coadministration of SEA with a Listeria monocytogenes vector expressing HIV-1 IIIB Gag (Lm-Gag) led to a significantly increased frequency of gamma interferon (IFN-γ)-producing CD8(+) and CD4(+) T cells in C57BL/6 mice compared to mice immunized with Lm-Gag only. These observations suggest that SEA contains, in addition to Th2-type and immune-suppressive molecules, substances that can act with the Lm-Gag vaccine to increase CTL and Th1-type vaccine-specific immune responses.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25520148      PMCID: PMC4308864          DOI: 10.1128/CVI.00514-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production.

Authors:  Daniel Elias; Sven Britton; Abraham Aseffa; Howard Engers; Hannah Akuffo
Journal:  Vaccine       Date:  2008-05-21       Impact factor: 3.641

2.  Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.

Authors:  G R Gunn; A Zubair; C Peters; Z K Pan; T C Wu; Y Paterson
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

3.  Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice.

Authors:  D Elias; H Akuffo; C Thors; A Pawlowski; S Britton
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  Expression of the SLAM family of receptors adapter EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens.

Authors:  Yasser A Aldhamen; Daniel M Appledorn; Sergey S Seregin; Chyong-jy J Liu; Nathaniel J Schuldt; Sarah Godbehere; Andrea Amalfitano
Journal:  J Immunol       Date:  2010-12-13       Impact factor: 5.422

5.  Use of DAF-displaying adenovirus vectors reduces induction of transgene- and vector-specific adaptive immune responses in mice.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Jennifer Zehnder; Tyler Voss; Sarah Godbehere; Andrea Amalfitano
Journal:  Hum Gene Ther       Date:  2011-04-18       Impact factor: 5.695

6.  Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice.

Authors:  Akram A Da'Dara; Norman Lautsch; Timothy Dudek; Vladimir Novitsky; Tun-Hou Lee; Myron Essex; Donald A Harn
Journal:  Vaccine       Date:  2006-04-18       Impact factor: 3.641

7.  Innate immune response in Th1- and Th2-dominant mouse strains.

Authors:  Hiroyuki Watanabe; Kousuke Numata; Takaaki Ito; Katsumasa Takagi; Akihiro Matsukawa
Journal:  Shock       Date:  2004-11       Impact factor: 3.454

8.  A comparative study on mouse MHC class I sequences detected in Schistosoma japonicum recovered from BALB/c (H-2d) and C57BL/6 (H-2b) mice.

Authors:  Atsuko Imase; Hiroshi Ohmae; Yukio Iwamura; Masashi Kirinoki; Hajime Matsuda
Journal:  Southeast Asian J Trop Med Public Health       Date:  2004-03       Impact factor: 0.267

9.  Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge.

Authors:  M Mata; Z J Yao; A Zubair; K Syres; Y Paterson
Journal:  Vaccine       Date:  2001-01-08       Impact factor: 3.641

10.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226

View more
  2 in total

1.  Role of T. cruzi exposure in the pattern of T cell cytokines among chronically infected HIV and Chagas disease patients.

Authors:  Tania Regina Tozetto-Mendoza; Dewton de Moraes Vasconcelos; Karim Yaqub Ibrahim; Ana Marli Christovam Sartori; Rita C Bezerra; Vera Lúcia Teixeira de Freitas; Maria Aparecida Shikanai-Yasuda
Journal:  Clinics (Sao Paulo)       Date:  2017-11       Impact factor: 2.365

Review 2.  Mucin-Type O-Glycosylation in Invertebrates.

Authors:  Erika Staudacher
Journal:  Molecules       Date:  2015-06-09       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.